Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm
- None.
- None.
New artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
“Given the high prevalence of patients with suspected HCM who remain undiagnosed, flagging and connecting them quickly to the right providers is critical to improve health outcomes,” said Matthew Martinez, MD, director of sports cardiology and HCM, Atlantic Health System. “The role of artificial intelligence in cardiology is growing exponentially and adding the HCM module to Viz.ai will help increase awareness and reach for HCM patients.”
The Viz HCM module automatically reviews routine electrocardiograms (ECGs) from across a health system to identify suspected HCM cases and notifies the appropriate cardiologists and care team on the Viz mobile application. Clinicians can then easily review the patient’s ECG, coordinate follow-up with an echocardiogram for diagnosis, and use the Viz Echo Viewer to review images and access echocardiogram reports. The HCM module is one of twelve FDA-cleared AI algorithms on the enterprise-wide, clinically validated Viz.ai Platform, which has been shown to increase access to treatments and improve patient outcomes across more than 1,400 hospitals in the US and
“Hypertrophic cardiomyopathy is a devastating disease that is often undetected until it is too late. The addition of Viz HCM to the Viz.ai Platform aims to improve outcomes for patients with HCM by getting them to the right specialist faster,” said Chris Mansi, MD, CEO and co-founder at Viz.ai. “We are thrilled with this De Novo approval, which establishes the new FDA category of cardiovascular machine learning-based notification software. The ongoing investment of innovative capabilities on our platform is why it continues to be the first choice of leading healthcare systems. With our AI-powered Viz HCM module, we look forward to realizing its promise in expediting detection and care of patients with this common, inherited heart disease.”
To learn more about Viz HCM, please join our upcoming webinar on September 13 at 7pm ET.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230815951202/en/
Laurie Masonson
laurie.masonson@finnpartners.com
Source: Viz.ai
FAQ
What is the name of the company mentioned in the press release?
What is the purpose of the Viz HCM module?
Who is financially supporting the deployment of the Viz HCM algorithm?
What does the Viz HCM module do?
How many hospitals has Viz.ai's platform been shown to improve patient outcomes in?